2018
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Eckardt K, Bansal N, Coresh J, Evans M, Grams M, Herzog C, James M, Heerspink H, Pollock C, Stevens P, Tamura M, Tonelli M, Wheeler D, Winkelmayer W, Cheung M, Hemmelgarn B, Participants C, Abu-Alfa A, Anand S, Arici M, Ballew S, Block G, Burgos-Calderon R, Charytan D, Das-Gupta Z, Dwyer J, Fliser D, Froissart M, Gill J, Griffith K, Harris D, Huffman K, Inker L, Jager K, Jun M, Kalantar-Zadeh K, Kasiske B, Kovesdy C, Krane V, Lamb E, Lerma E, Levey A, Levin A, Mauro J, Nash D, Navaneethan S, O’Donoghue D, Obrador G, Pecoits-Filho R, Robinson B, Schäffner E, Segev D, Stengel B, Stenvinkel P, Tangri N, Tentori F, Tsukamoto Y, Turakhia M, Vazquez M, Wang A, Williams A. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 1281-1292. PMID: 29656903, PMCID: PMC5998808, DOI: 10.1016/j.kint.2018.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateKidney replacement therapyCKD G4Kidney failureFiltration rateRisk factorsGlobal outcomeTraditional CVD risk factorsCKD Prognosis ConsortiumCVD risk factorsCardiovascular disease eventsPrognosis of patientsOptimal therapeutic strategyControversies ConferenceCohort studyCVD outcomesHeart failureVariable prognosisClinical outcomesTherapeutic challengeKidney diseasePrognostic valueReplacement therapyInternational expert groupPatient preferences
2008
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*
Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*. Current Medical Research And Opinion 2008, 24: 1091-1100. PMID: 18328118, DOI: 10.1185/030079908x280653.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseErythropoiesis-stimulating agentsHealth-related qualityDarbepoetin alfaWeek 52Week 12Kidney diseasePatients' health-related qualityGeneral CKD populationQ2W darbepoetin alfaWeek darbepoetin alfaGlomerular filtration rateSingle-arm studyBenefits of treatmentMean Hb concentrationYears of ageSubject inclusion criteriaCKD populationCreatinine clearanceHemoglobin levelsHb targetHb levelsHRQOL measuresFiltration rateInclusion criteriaThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio